Serina Therapeutics Inc (SER) Q2 2024 Earnings Report

Serina Therapeutics reported a quarterly revenue of $51,000 for QQ2 2024, a figure that remains negligible relative to the company’s operating costs. The company posted a negative gross profit of $6,000 as cost of revenue exceeded revenue, while research and development (R&D) and general and administrative (G&A) expenses remained elevated at $1.594 million and $2.323 million, respectively. Despite a negative operating income of $3.867 million, Serina recognizable an apparently sizable positive net income of $5.204 million for the quarter, driven by a substantial non-operating income item of $9.043 million that more than offset the operating imbalance. Earnings per share (EPS) amounted to $0.61 (GAAP), with diluted EPS of $0.51.

From a liquidity and balance-sheet perspective, the company carries meaningful leverage and a largest balance sheet exposure to liabilities versus assets. Total assets stood at $10.708 million against total liabilities of $27.101 million, yielding negative stockholders’ equity of $(16.363) million. Cash and cash equivalents were $6.064 million at period end, with net debt of $5.647 million. The cash flow statement shows negative operating cash flow of $(8.009) million, reflecting significant working-capital uses and non-cash adjustments, though financing activities added $5.367 million, producing a net decrease in cash of $(2.642) million for the quarter. The company’s near-term trajectory will depend on progress in its early-stage pipeline (notably SER252 and related POZ technologies) and its ability to secure additional financing or strategic partnerships to fund ongoing R&D.

Key takeaways for investors: (i) the quarter’s net income is heavily distorted by a one-time or non-operating gain; (ii) underlying operating performance remains loss-making with a substantial burn rate; (iii) liquidity is challenged by near-term liabilities and negative equity; (iv) any meaningful upside will hinge on clinical progress, data readouts, and potential financing/licensing arrangements. Given the current mix of a fragile balance sheet and limited revenue generation, the stock presents high-risk, high-uncertainty exposure, characteristic of early-stage biotechnology businesses.